Phase I Trial: T4 Immunotherapy of Head and Neck Cancer
King's College London
King's College London
Suzhou Genhouse Bio Co., Ltd.
Wellmarker Bio
Sunnybrook Health Sciences Centre
The Netherlands Cancer Institute
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Centre Georges Francois Leclerc
Southern Tohoku BNCT Research Center
Wellmarker Bio
Revolution Medicines, Inc.
Imperial College London
Silverback Therapeutics
Corregene Biotechnology Co., Ltd
Institut Català d'Oncologia
University Hospital Tuebingen
ISU Abxis Co., Ltd.
Ruijin Hospital
Critical Outcome Technologies Inc.
Mie University
Wuxi No. 4 People's Hospital
Rigshospitalet, Denmark
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Yamanashi
Poniard Pharmaceuticals
Novacea